Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 6,478 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Prophylaxis A Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

Evaluation of Circles of Safety

NCT07526142
View directory record Official record
Conditions
Child Abuse Sexual
Interventions
Circles of Safety
Behavioral
Lead sponsor
Center for Violence Prevention Research Inc
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Safety and Pharmacokinetics of Efmarodocokin Alfa in Combination With Standard of Care in Participants Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

NCT04539470
View directory record Official record
Conditions
Acute Graft-versus-host Disease
Interventions
Efmarodocokin Alfa
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Duarte, California • Los Angeles, California • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2024 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stopping TSC Onset and Progression 2: Epilepsy Prevention in TSC Infants

NCT04595513
View directory record Official record
Conditions
Tuberous Sclerosis Complex, Epilepsy
Interventions
TAVT-18 (sirolimus)
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Day to 6 Months
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 24, 2026, 2:32 PM EDT
Not yet recruiting Not applicable Interventional

Nurse-Led PrEP Initiation Among Incarcerated Individuals

NCT07781423
View directory record Official record
Conditions
HIV Prevention Program, Pre-Exposure Prophylaxis (PrEP)
Interventions
Nurse-Led Intervention, Patient Navigation Intervention, Standard-of-care (SoC)
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Not yet recruiting No phase listed Observational

Disease Intervention Specialist (DIS) for SUD

NCT07875361
View directory record Official record
Conditions
Substance Use Disorder (SUD), Opioid Use Disorder, Alcohol Use Disorder (AUD), Drug Use, Overdose
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
1,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional

Implant for Augmentation of Cerebral Blood Flow Trial, Effectiveness and Safety in a 24 Hour Window

NCT00826059
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Active Sphenopalatine Ganglion (SPG) Stimulation, Sham Sphenopalatine Ganglion (SPG) Stimulation
Device
Lead sponsor
BrainsGate
Industry
Eligibility
40 Years to 85 Years
Enrollment
1,078 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
7
States / cities
Sarasota, Florida • Winfield, Illinois • Greensboro, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Oct 24, 2026, 2:32 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Overvaluation of Weight and Shape Intervention vs The Body Project

NCT07678554
View directory record Official record
Conditions
Body Image, Mental Health Outcomes, Eating Disorders, Body Dysmorphic Disorders, Self-esteem
Interventions
Priorities, Body Project
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
14 Years to 22 Years · Female only
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome

NCT03670966
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Cyclophosphamide, Total-Body Irradiation, Peripheral Blood Stem Cell Transplantation, Bone Marrow Transplantation, Mycophenolate Mofetil, Recombinant Granulocyte Colony-Stimulating Factor, Fludarabine Phosphate, Tacrolimus, Bone Marrow Aspiration and Biopsy, Biospecimen Collection
Biological · Drug · Radiation + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Healthy Homes Healthy Children (H3C)

NCT01740622
View directory record Official record
Conditions
Injury in the Home
Interventions
Injury Prevention Measures
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
6 Months to 36 Months
Enrollment
520 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 29, 2018 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Health at Every Size vs a Behavioral Weight Loss Approach for Obese Women

NCT00769717
View directory record Official record
Conditions
Obesity
Interventions
Wellness-Centered (HUGS), Weight-Centered (LEARN)
Behavioral
Lead sponsor
The Reading Hospital and Medical Center
Other
Eligibility
30 Years to 45 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2011
U.S. locations
1
States / cities
West Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 3, 2019 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Workplace-Sponsored Program to Reduce Obesity

NCT00123513
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases
Interventions
Diet, Exercise, Environment
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
3,938 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Interventions to Improve the HIV PrEP Cascade Among Methamphetamine Users

NCT03584282
View directory record Official record
Conditions
HIV/AIDS, Adherence, Medication, Drug Use
Interventions
Text Messaging, Peer Navigation
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose Ranging Study to Determine the Safety, Reactogenicity and Immunogenicity of Typhoid Fever Vaccine (Ty800) in Healthy Adult Subjects

NCT00498654
View directory record Official record
Conditions
Typhoid Fever
Interventions
Ty800 (Salmonella typhi) Oral Vaccine
Biological
Lead sponsor
Avant Immunotherapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
5
States / cities
San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2008 · Synced Oct 24, 2026, 2:32 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Testing Family Firearm Secure Storage Training (FFAST) to Prevent Suicide

NCT07692854
View directory record Official record
Conditions
Lethal Means Safety, Brief Intervention, Concern Significant Others
Interventions
The Family Firearms Secure storage Training (FFAST) Intervention, Health and Stress Counseling
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

BullyDown, a Text Messaging-based Bullying Prevention Program for Middle School-aged Youth

NCT06017050
View directory record Official record
Conditions
Bullying
Interventions
BullyDown, Attention-matched control
Behavioral
Lead sponsor
Center for Innovative Public Health Research
Other
Eligibility
12 Years to 14 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
San Clemente, California • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 5, 2025 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 3 Interventional Results available

BAY81-8973 Pediatric Safety and Efficacy Trial

NCT01311648
View directory record Official record
Conditions
Haemophilia A
Interventions
Recombinant Factor VIII (Kovaltry, BAY81-8973)
Biological
Lead sponsor
Bayer
Industry
Eligibility
0 Years to 12 Years · Male only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
4
States / cities
New Orleans, Louisiana • Cincinnati, Ohio • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 24, 2026, 2:32 PM EDT
Withdrawn Phase 1 Interventional

Methotrexate For The Prevention and Treatment of Proliferative Vitreoretinopathy in Pediatric Patients

NCT04830878
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Methotrexate
Drug
Lead sponsor
Stanford University
Other
Eligibility
Up to 18 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Cranial Electrotherapy Stimulation: Piloting a Road to PTSD Prevention in First Responders

NCT06203717
View directory record Official record
Conditions
Adults, Firefighters
Interventions
Alpha-Stim AID cranial electrotherapy stimulation
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 56 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 2Phase 3 Interventional

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

NCT00041925
View directory record Official record
Conditions
Peripheral Vascular Diseases, Arterial Occlusive Diseases, Ischemia, Graft Occlusion, Vascular, Hyperplasia
Interventions
CGT003 (E2F Duplex Decoy)
Drug
Lead sponsor
Anesiva, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
116
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2005 · Synced Oct 24, 2026, 2:32 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Testing Strategies to Improve Substance Misuse Prevention Research Use in State Policy Contexts

NCT06856148
View directory record Official record
Conditions
Substance Abuse, Substance Use Disorders, Prevention, Legislation, Use of Research Evidence
Interventions
Intervention: RPC Group, Active Comparator: Control Group
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
Not listed
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
University Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 6, 2025 · Synced Oct 24, 2026, 2:32 PM EDT
Completed Phase 2 Interventional Results available

Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation

NCT02458235
View directory record Official record
Conditions
Acute Myelogenous Leukemia, Acute Lymphoid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
azacitidine, donor lymphocyte infusion
Drug · Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 29 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 12, 2020 · Synced Oct 24, 2026, 2:32 PM EDT
Completed No phase listed Observational

A Study to Evaluate the Impact of Stopping Treatment for the Prevention of Pneumonia in HIV-Positive Patients Receiving Anti-HIV Drugs Who Have Increased CD4 Cell Counts

NCT00000908
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
53
States / cities
Birmingham, Alabama • Harbor City, California • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 24, 2026, 2:32 PM EDT
Recruiting Phase 1 Interventional

Ruxolitinib With and Without CTLA-4 Ig Abatacept for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

NCT06008808
View directory record Official record
Conditions
Graft Vs Host Disease, Graft-versus-host-disease, Graft Versus Host Disease
Interventions
Ruxolitinib, Abatacept
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 24, 2026, 2:32 PM EDT
Active, not recruiting No phase listed Observational

Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy

NCT02633943
View directory record Official record
Conditions
Transfusion-dependent Beta-Thalassemia
Interventions
Safety and efficacy assessments
Other
Lead sponsor
Genetix Biotherapeutics Inc.
Industry
Eligibility
0 Years to 50 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2035
U.S. locations
6
States / cities
Oakland, California • Chicago, Illinois • Bethesda, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Oct 24, 2026, 2:32 PM EDT